Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $1.25 USD
Change Today -0.07 / -5.30%
Volume 32.1K
DYAI On Other Exchanges
Symbol
Exchange
OTC US
As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

dyadic international inc (DYAI) Snapshot

Open
$1.32
Previous Close
$1.32
Day High
$1.33
Day Low
$1.24
52 Week High
08/18/14 - $1.87
52 Week Low
12/11/14 - $0.80
Market Cap
42.6M
Average Volume 10 Days
48.3K
EPS TTM
$-0.18
Shares Outstanding
34.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DYADIC INTERNATIONAL INC (DYAI)

dyadic international inc (DYAI) Related Bloomberg News

View More Bloomberg News

dyadic international inc (DYAI) Related Businessweek News

No Related Businessweek News Found

dyadic international inc (DYAI) Details

Dyadic International, Inc., a biotechnology company, discovers, develops, manufactures, and sells enzymes, proteins, peptides, and other bio-molecules for the bioenergy, biochemical, industrial enzyme, and biopharmaceutical industries. It primarily manufactures and sells liquid and dry enzyme products for use in the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles, and bio fuels industries. The company utilizes an integrated technology platform based on its patented and proprietary C1 fungus technology, which enables the development and manufacture of various proteins and enzymes, as well as other biological products, such as antibodies, vaccines, proteins, and polypeptides for the biopharmaceutical industry. It also develops fungal strains that produce enzymes used in animal health and nutrition applications. The company has operations in the United States and the Netherlands. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

dyadic international inc (DYAI) Top Compensated Officers

Chief Executive Officer, President, Founder, ...
Total Annual Compensation: $385.4K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $195.4K
Vice President of Operations
Total Annual Compensation: $225.0K
Compensation as of Fiscal Year 2013.

dyadic international inc (DYAI) Key Developments

Dyadic International Appoints Jack Kaye to the Board of Directors, Effective April 1, 2015

Dyadic International, Inc. appointed Jack Kaye to the Board of Directors, effective April 1, 2015. Mr. Kaye will serve on the audit and compensation committees. With the addition of Mr. Kaye, there will be seven members on the Dyadic Board. Mr. Kaye currently the Chairman of the Audit Committee of Keryx Biopharmaceuticals, Inc.

Dyadic International, Inc. Announces Consolidated Financial Results for the Year Ended December 31, 2014

Dyadic International, Inc. announced consolidated financial results for the year ended December 31, 2014. Total revenue decreased to $12.5 million compared to $17.1 million for fiscal year 2013. The decrease in total revenue is primarily due to the $6.0 million BASF upfront license fee in 2013. This decrease was partially offset by 53% growth in research and development revenue of $710,000, and the receipt of $700,000 in milestone payments from Abengoa and BASF. Excluding the 2013 upfront BASF license fee, revenue increased $1.4 million, or 12%, to $12.5 million compared to $11.1 million for the same period last year. Net loss for the fiscal year ended December 31, 2014 was $6.0 million, or $0.18 per basic and diluted share, compared to a net loss of $428,000, or $0.01 per basic and diluted share, for the same period a year ago. Loss from operations was $5,324,937 compared to income from operations of $556,502 a year ago. Loss before provision for income taxes was $5,980,089 compared to $428,050 a year ago. Net cash used in operating activities was $6,200,067 compared to net cash provided by operating activities of $5,095,854 for the last year. Purchases of fixed assets were $258,809 compared to $312,145 for the last year.

Dyadic International, Inc. to Report Q4, 2014 Results on Mar 11, 2015

Dyadic International, Inc. announced that they will report Q4, 2014 results at 5:00 PM, US Eastern Standard Time on Mar 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DYAI:US $1.25 USD -0.07

DYAI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Koninklijke DSM NV €51.01 EUR +0.06
Lonza Group AG SFr.134.10 CHF +1.00
Merck KGaA €96.79 EUR +0.76
Novozymes A/S kr310.50 DKK +2.70
Teva Pharmaceutical Industries Ltd $62.17 USD +1.75
View Industry Companies
 

Industry Analysis

DYAI

Industry Average

Valuation DYAI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYADIC INTERNATIONAL INC, please visit www.dyadic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.